OMEROS CORP Increase (Decrease) in Other Noncurrent Liabilities
OMEROS CORP (OMER) reported Increase (Decrease) in Other Noncurrent Liabilities of $668.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities · last filed 2022-03-01
- OMEROS CORP increase (decrease) in other noncurrent liabilities for the quarter ending 2014-09-30 was $262.00K, a 74.46% decline year-over-year.
- OMEROS CORP increase (decrease) in other noncurrent liabilities for the quarter ending 2014-06-30 was $262.00K, a 86.02% decline year-over-year.
- OMEROS CORP increase (decrease) in other noncurrent liabilities for the quarter ending 2014-03-31 was $263.00K, a 202.30% increase year-over-year.
- OMEROS CORP increase (decrease) in other noncurrent liabilities for the quarter ending 2013-09-30 was $1.03M, a 1151.22% increase year-over-year.
- OMEROS CORP increase (decrease) in other noncurrent liabilities for fiscal 2021 was $668.00K.
| Period end | Increase (Decrease) in Other Noncurrent Liabilities 3 month | Increase (Decrease) in Other Noncurrent Liabilities 6 month | Increase (Decrease) in Other Noncurrent Liabilities 9 month | Increase (Decrease) in Other Noncurrent Liabilities 12 month |
|---|---|---|---|---|
| 2021-12-31 | $668.00K 10-K · filed 2022-03-01 | |||
| 2014-09-30 | $262.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $524.00K derived: sum of 2 quarters · filed 2014-11-10 | $787.00K 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $262.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $525.00K 10-Q · filed 2014-08-11 | ||
| 2014-03-31 | $263.00K 10-Q · filed 2014-05-12 | |||
| 2013-09-30 | $1.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $2.90M derived: sum of 2 quarters · filed 2014-11-10 | $2.99M 10-Q · filed 2014-11-10 | |
| 2013-06-30 | $1.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $1.96M 10-Q · filed 2014-08-11 | ||
| 2013-03-31 | $87.00K 10-Q · filed 2014-05-12 | |||
| 2012-09-30 | $82.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $30.00K derived: sum of 2 quarters · filed 2013-11-07 | $3.09M 10-Q · filed 2013-11-07 | |
| 2012-06-30 | -$52.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $3.01M 10-Q · filed 2013-08-09 | ||
| 2012-03-31 | $3.06M 10-Q · filed 2012-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |